摘要
肝纤维化是慢性肝病的共同病理学过程,其导致的肝硬化、肝衰竭甚至肝癌的病死人数在世界范围内逐年增长。目前评估肝纤维化的检测方法主要包括肝组织学检查、影像学和血清学标志物,但是在临床应用上均有诸多局限性。近年有关非编码RNA和外泌体等与肝纤维化发生发展的研究日益增多,且被认为是具有潜在临床应用前景的新型分子标志物。现结合相关进展进行初步评估,以期为肝纤维化的早期诊断和治疗提供参考。
Liver fibrosis is a common pathological process of chronic liver disease,and the number of deaths from liver cirrhosis,liver failure and liver cancer is increasing year-by-year worldwide.Presently,the detection methods to evaluate hepatic fibrosis mainly include hepatic histological examination,imaging and serum markers,but all these have many limitations in clinical aspects.Recently,there have been more and more studies related to the development of non-coding RNA,exosomes and liver fibrosis that are considered as a new type of biomolecular markers with potential clinical application.Herein,we did a preliminary assessment in conjunction with relevant advances to provide a reference for the early diagnosis and treatment of liver fibrosis.
作者
洪伟
韩涛
时哲敏
章坤
Hong Wei;Han Tao;Shi Zhemin;Zhang Kun(School of Basic Sciences,Tianjin Medical University,Tianjin 300070,China;Tianjin Third Central Hospital,Tianjin Key Laboratory of Artificial Cells,Artificial Cell Engineering Technology Research Center of Public Health Ministry,Tianjin 300170,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2019年第6期411-414,共4页
Chinese Journal of Hepatology
基金
国家科技部重大专项(2017ZX10203201-007)
国家自然科学基金面上项目(81670558,81870429).